US drugmaker Pfizer released good news on Wednesday stating that its COVID-19 vaccine has been tested and passed with flying colors. What’s more, it can be ready to go by the end of the month.
According to the New York Post, the drug is doing far better than they anticipated with a 95 percent success rate over the 90 percent they originally predicted. Pfizer also said that the vaccine had no serious side effects with the exception of fatigue and maybe a bit of a headache:
After completing their Phase 3 trial, the companies said there have been no serious side effects among the 41,135 adults who received two doses. The most common reactions were that 3.7 percent of them experienced fatigue and 2 percent had a headache, they said.
“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic,” Pfizer CEO Dr. Albert Bourla said in the statement, NBC News reported.
“With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world,” he added.
The New York Post noted that they will be submitting a request “within days” for emergency use authorization with the US Food and Drug Administration for distribution of the vaccine. Pfizer says that 50 million doses will be created this year with 1.3 billion more to be created in 2021.
The bad news?
Only half that supply will get to Americans this year as 12.5 million people will get the vaccine while everyone else will have to wait till after the holidays to receive it. Those that do receive the shot will get it for free thanks to a deal with the Trump administration.
Not having any side effects will be a very large deal maker for many, especially many Republicans, 49 percent of whom were standoffish about receiving the vaccine, with the main concern being the safety of the drug at 26 percent.
How these numbers will now shift remains to be seen, but it would appear that Pfizer has now set America on a path to resisting the virus.